These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 15719584)

  • 1. Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
    Michaud LB
    Am J Health Syst Pharm; 2005 Feb; 62(3):266-73. PubMed ID: 15719584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT; Robert NJ
    MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
    Goss PE
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PubMed ID: 11916231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
    Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
    Eisen A; Trudeau M; Shelley W; Messersmith H; Pritchard KI
    Cancer Treat Rev; 2008 Apr; 34(2):157-74. PubMed ID: 18164821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS
    Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
    Buzdar AU
    Clin Cancer Res; 2004 Jan; 10(1 Pt 2):355S-61S. PubMed ID: 14734491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
    Buzdar A
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S42-8. PubMed ID: 12756078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
    Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
    Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit.
    Henderson IC
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):31-4. PubMed ID: 15719599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
    Chung CT; Carlson RW
    Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S18-23. PubMed ID: 15347435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.